Podocalyxin expression in malignant astrocytic tumors

Biochemical and Biophysical Research Communications

Volumn 374, Issue 2, 2008, Pages 394-398

  Hayatsu, Norihito ^a   Kaneko, Mika Kato ^b   Mishima, Kazuhiko ^c   Nishikawa, Ryo ^c   Matsutani, Masao ^c   Price, Janet E ^b   Kato, Yukinari ^b  

^a KYOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

Author keywords

Astrocytic tumor; Glioblastoma; Keratan sulfate; Podocalyxin; Proteoglycan

Indexed keywords

PODOCALYXIN;

ARTICLE; ASTROCYTOMA; CELL PROLIFERATION; DISEASE MARKER; ENDOTHELIUM CELL; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL; TUMOR GROWTH; WESTERN BLOTTING;

ASTROCYTOMA; BLOTTING, WESTERN; CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION; PROGNOSIS; RNA, MESSENGER; SIALOGLYCOPROTEINS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 48349131661     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.07.049     Document Type: Article

References (25)

1. Kleihues P., Burger P.C., Collines V.P., Newcomb E.W., Ohagi H., and Cavenee W.K. Astrocytic Tumors, Glioblastma (2000), International Agency for Research on Cancer Press, Lyons, France pp. 29-39
2. Giese A., Bjerkvig R., Berens M.E., and Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J. Clin. Oncol. 21 (2003) 1624-1636
3. Kleihues P., and Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-oncology 1 (1999) 44-51
4. Kerjaschki D., Sharkey D.J., and Farquhar M.G. Identification and characterization of podocalyxin-the major sialoprotein of the renal glomerular epithelial cell. J. Cell Biol. 98 (1984) 1591-1596
5. Schnitzer J.E., Shen C.P., and Palade G.E. Lectin analysis of common glycoproteins detected on the surface of continuous microvascular endothelium in situ and in culture: identification of sialoglycoproteins. Eur. J. Cell Biol. 52 (1990) 241-251
6. Hara T., Nakano Y., Tanaka M., Tamura K., Sekiguchi T., Minehata K., Copeland N.G., Jenkins N.A., Okabe M., Kogo H., Mukouyama Y., and Miyajima A. Identification of podocalyxin-like protein 1 as a novel cell surface marker for hemangioblasts in the murine aorta-gonad-mesonephros region. Immunity 11 (1999) 567-578
7. Miettinen A., Solin M.L., Reivinen J., Juvonen E., Vaisanen R., and Holthofer H. Podocalyxin in rat platelets and megakaryocytes. Am. J. Pathol. 154 (1999) 813-822
8. Doyonnas R., Kershaw D.B., Duhme C., Merkens H., Chelliah S., Graf T., and McNagny K.M. Anuria, omphalocele, and perinatal lethality in mice lacking the CD34-related protein podocalyxin. J. Exp. Med. 194 (2001) 13-27
9. Takeda T., Go W.Y., Orlando R.A., and Farquhar M.G. Expression of podocalyxin inhibits cell-cell adhesion and modifies junctional properties in Madin-Darby canine kidney cells. Mol. Biol. Cell 11 (2000) 3219-3232
10. Somasiri A., Nielsen J.S., Makretsov N., McCoy M.L., Prentice L., Gilks C.B., Chia S.K., Gelmon K.A., Kershaw D.B., Huntsman D.G., McNagny K.M., and Roskelley C.D. Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression. Cancer Res. 64 (2004) 5068-5073
11. Chen X., Higgins J., Cheung S.T., Li R., Mason V., Montgomery K., Fan S.T., van de Rijn M., and So S. Novel endothelial cell markers in hepatocellular carcinoma. Mod. Pathol. 17 (2004) 1198-1210
12. Ney J.T., Zhou H., Sipos B., Buttner R., Chen X., Kloppel G., and Gutgemann I. Podocalyxin-like protein 1 expression is useful to differentiate pancreatic ductal adenocarcinomas from adenocarcinomas of the biliary and gastrointestinal tracts. Hum. Pathol. 38 (2007) 359-364
13. Stanhope-Baker P., Kessler P.M., Li W., Agarwal M.L., and Williams B.R. The Wilms tumor suppressor-1 target gene podocalyxin is transcriptionally repressed by p53. J. Biol. Chem. 279 (2004) 33575-33585
14. Casey G., Neville P.J., Liu X., Plummer S.J., Cicek M.S., Krumroy L.M., Curran A.P., McGreevy M.R., Catalona W.J., Klein E.A., and Witte J.S. Podocalyxin variants and risk of prostate cancer and tumor aggressiveness. Hum. Mol. Genet. 15 (2006) 735-741
15. Schopperle W.M., Kershaw D.B., and DeWolf W.C. Human embryonal carcinoma tumor antigen, Gp200/GCTM-2, is podocalyxin. Biochem. Biophys. Res. Commun. 300 (2003) 285-290
16. Kelley T.W., Huntsman D., McNagny K.M., Roskelley C.D., and Hsi E.D. Podocalyxin: a marker of blasts in acute leukemia. Am. J. Clin. Pathol. 124 (2005) 134-142
17. Sizemore S., Cicek M., Sizemore N., Ng K.P., and Casey G. Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin. Cancer Res. 67 (2007) 6183-6191
18. Hayatsu N., Ogasawara S., Kaneko M.K., Kato Y., and Narimatsu H. Expression of highly sulfated keratan sulfate synthesized in human glioblastoma cells. Biochem. Biophys. Res. Commun. 368 (2008) 217-222
19. Kato Y., Hayatsu N., Kaneko M.K., Ogasawara S., Hamano T., Takahashi S., Nishikawa R., Matsutani M., Mishima K., and Narimatsu H. Increased expression of highly sulfated keratan sulfate synthesized in malignant astrocytic tumors. Biochem. Biophys. Res. Commun. 369 (2008) 1041-1046
20. Schopperle W.M., and DeWolf W.C. The TRA-1-60 and TRA-1-81 human pluripotent stem cell markers are expressed on podocalyxin in embryonal carcinoma. Stem Cells 25 (2007) 723-730
21. Mishima K., Kato Y., Kaneko M.K., Nishikawa R., Hirose T., and Matsutani M. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol. (Berlin) 111 (2006) 483-488
22. J. Achenbach, M. Mengel, I. Tossidou, I. Peters, J. K. Park, M. Haubitz, J. H. Ehrich, H. Haller, M. Schiffer, Parietal epithelia cells in the urine as a marker of disease activity in glomerular diseases, Nephrol. Dial. Transpl., in press.
23. Choo A.B., Tan H.L., Ang S.N., Fong W.J., Chin A., Lo J., Zheng L., Hentze H., Philp R.J., Oh S.K., and Yap M. Selection against undifferentiated human embryonic stem cells by a cytotoxic antibody recognizing podocalyxin-like protein-1. Stem Cells 26 (2008) 1454-1463
24. Kato Y., Kaneko M.K., Kunita A., Ito H., Kameyama A., Ogasawara S., Matsuura N., Hasegawa Y., Suzuki-Inoue K., Inoue O., Ozaki Y., and Narimatsu H. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci. 99 (2008) 54-61
25. Kato Y., Kaneko M.K., Kuno A., Uchiyama N., Amano K., Chiba Y., Hasegawa Y., Hirabayashi J., Narimatsu H., Mishima K., and Osawa M. Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. Biochem. Biophys. Res. Commun. 349 (2006) 1301-1307